| Ávila et al., 2025 |
Prospective cohort |
Sixty-nine patients with Chagas cardiomyopathy; 41 (59.4%) female; aged 53.70 ± 9.66; LVEF: 47.84 ± 16.6%. NYHA I: n = 43 (62.3%) NYHA II: n = 26 (37.7%) |
NYHA functional class (categorical: I-II) |
Per one-class increase in NYHA functional class |
Composite cardiovascular outcome (cardiac death, heart transplantation, or stroke) |
43.81 ± 1.21 months |
NYHA: HR = 0.80; CI: 0.27-2.35; p = 0.688*Z |
High |
| Costa et al., 2018 |
Prospective cohort |
Forty-nine patients with Chagas cardiomyopathy; 21 (43%) female; aged 50.0 ± 7.0; LVEF: 36.0% (31.0%-41.0%). NYHA I: n = 28 (57%) NYHA II: n = 16 (33%) NYHA III: n = 5 (10%) |
NYHA II and III |
NYHA I |
Cardiac mortality |
39 ± 14 months |
NYHA I vs. II and III*: HR = 1.0; CI: 0.2-1.6; p = 0.597 |
Low |
| Costa et al., 2019 |
Prospective cohort |
Seventy-five patients with Chagas cardiomyopathy; 64 female; aged 48.4 ± 8.0; LVEF: 41.0% (35.0%-53.5%). NYHA I: n = 45 (60%) NYHA II: n = 24 (32%) NYHA III: n = 6 (8%) |
NYHA |
Per one-class increase in NYHA functional class |
Cardiovascular events, defined as cardiac death, heart transplantation, or ischemic event |
41 ± 12 months |
NYHA: HR = 0.92; CI: 0.46-1.84; p = 0.823* |
High |
| Costa Rassi et al., 2017 |
Prospective cohort |
Sixty patients with Chagas cardiomyopathy; 24 (45%) female; aged 52.6 ± 9.4; LVEF: 27.5% (25.3%-28.9%). All NYHA II or III |
NYHA III |
NYHA II |
All-cause mortality |
7.5 years |
NYHA II vs. III: HR = 1.34; CI: 0.76-2.36; p = 0.311 |
High |
| Ferreira et al., 2020 |
Prospective cohort |
One-thousand six-hundred thirty-seven patients with Chagas cardiomyopathy; 876 (53.5%) aged over 60; LVEF: not reported. NYHA I: n = 904 (55.7%) NYHA II-IV: n = 718 (44.3%) |
NYHA II-IV |
NYHA I |
Cardiovascular events (characterized as: death from all causes, development of atrial fibrillation, or pacemaker implantation) |
2 years |
NYHA II-IV: OR = 2.007; CI: 1.402-2.873; p < 0.001 |
High |
| Gali et al., 2019 |
Prospective inception cohort after ICD implantation |
Eighty-nine patients with Chagas cardiomyopathy underwent ICD placement; aged 56 ± 11 years; LVEF: 42% ± 12%. NYHA I and II: n = 88 (98%) NYHA III: n = 1 (2%) |
NYHA III |
NYHA I and II |
All-cause mortality or heart transplantation |
59 ± 27 months |
NYHA III*: HR = 11.69; CI: 1.44-95.00; p = 0.02 |
Moderate |
| Lage et al., 2025 |
Prospective cohort |
Five-hundred seventeen patients with Chagas cardiomyopathy; 218 (42%) female; median age 54 (43-62; LVEF: median 39% (29%-50%). NYHA I and II: n = 394 (76%) NYHA III and IV: n = 124 (24%) |
NYHA III and IV |
NYHA I and II |
Occurrence of stroke |
4.8 years (IQR, 1.1-7.1 |
NYHA III-IV: HR = 1.69; CI: 0.80-3.55; p = 0.167 |
High |
| Lira et al., 2025 |
Retrospective cohort |
One-hundred seventy-eight patients with Chagas cardiomyopathy; 80 (44.9%) female; median age 60.0 (52.0-67.0); LVEF: median 30.0% (25.0%-35.0%). NYHA I: n = 61 (34.3%) NYHA II: 77 (43.3%) NYHA III: 33 (18.5%) NYHA IV: 7 (3.9%) |
NYHA functional class (categorical: I-IV) |
Per one-class increase in NYHA functional class |
Event-free survival (total mortality and heart transplantation) |
15 years |
NYHA I-IV: HR = 1,62; CI: 1,19-2,21; p = 0.002 |
High |
| Nunes et al., 2004 |
Prospective cohort |
Ninety-three patients with Chagas cardiomyopathy; aged 47.3 ± 12.9. NYHA: 1.8 ± 0.8* |
NYHA II and III |
NYHA I |
Cardiovascular mortality |
21.1 ± 10.8 months |
NYHA II, III, and IV: RR = 5.02; CI: 1.3-19.8; p = 0.02 |
High |
| Nunes et al., 2008 |
Prospective cohort |
One-hundred sixty patients with Chagas cardiomyopathy; aged 48.5 ± 12.3; LVEF: 36.9 ± 12.5%. NYHA I and II: n = 66 (79%) NYHA III and IV: n = 33 (21%) |
NYHA III and IV |
NYHA I and II |
Cardiovascular mortality/sudden death |
34 ± 23 months |
NYHA III-IV: HR = 2.15; CI: 1.16-4.29; p = 0.030 |
High |
| Di Lorenzo Oliveira et al., 2020 |
Prospective cohort |
One-thousand five-hundred eighty-four patients with Chagas cardiomyopathy; aged 59.4 ± 12.7. NYHA I: n = 836 (54%) NYHA II to IV: n = 715 (46%) |
NYHA II-IV |
NYHA I |
All-cause mortality |
2 years |
NYHA II-IV: HR = 1.628; CI: 1.088-2.437; p = 0.018 |
High |
| Peixoto et al., 2018 |
Prospective cohort |
Three-hundred ninety-six patients with Chagas cardiomyopathy and pacemaker; aged 62.5 ± 12.0; LVEF ≤ 43%: 132 (33.3%). NYHA I-II: n = 376 (94.9%) NYHA III-IV: n = 20 (5.1%) |
NYHA III-IV |
NYHA I and II |
All-cause mortality |
1.9 years (IQR, 1.6-2.4) |
NYHA III-IV: OR = 6.71; CI: 1.95-23.20; p = 0.003 |
Low |
| Lima Peixoto et al., 2024 |
Prospective cohort |
Five-hundred fifty-five patients; mean age 63.3 ± 12.0 years. NYHA I-II: n = 528 (95.0%) NYHA III-IV: n = 27 (5.0%) |
NYHA III-IV. |
NYHA I-II |
All-cause mortality |
3.7 ± 1.5 years |
NYHA III-IV: HR = 2.16; CI: 1.16-4.00; p = 0.014 |
High |
| Pereira et al., 2014 |
Prospective inception cohort after ICD implantation |
Sixty-five patients with Chagas cardiomyopathy after ICD implantation; aged 56 ± 11.9; LVEF > 55%: 12 (18.5%), LVEF 45%-55%: 5 (7.7%), LVEF 30%-44%: 15 (23.1%), LVEF < 30%: 33 (50.8%). NYHA I: n = 13 (20%) NYHA II: n = 25 (38.5%) NYHA III: n = 18 (27.5%) NYHA IV: n = 9 (13.8%) |
NYHA IV |
NYHA I-III |
All-cause mortality |
40 ± 26.8 months |
NYHA IV: HR = 3.5; CI: 0.9-14.4; p = 0.074 |
High |
| Pereira et al., 2024 |
Prospective inception cohort after ICD implantation |
One-hundred seventeen patients with Chagas cardiomyopathy after ICD implantation; median age 55 (48-64); LVEF normal: 18 (15.4%), LVEF mild: 6 (13.7%), LVEF moderate: 38 (32.5%), LVEF severe: 45 (38.5%). NYHA I: n = 20 (17.1%) NYHA II: n = 61 (52.1%) NYHA III: n = 29 (24.8%) NYHA IV: n = 7 (6%) |
NYHA III |
NYHA I-II |
All-cause mortality |
61 (25-121) months |
NYHA III vs. I-II: HR = 1.5; CI: 0.8-3.1; p = 0.21 NYHA IV vs. I-II: HR = 5.4; CI: 1.6-18.5; p = 0.007 |
Moderate |
| Prado et al., 2010 |
Prospective cohort |
Ninety-six patients with Chagas cardiomyopathy; median age 57 (IQR, 47.1-61); LVEF > 55%: 12 (18.5%), LVEF 45%-55%: 5 (7.7%), LVEF 30%-44%: 15 (23.1%), LVEF < 30%: 33 (50.8%). NYHA I-II: 34 (35.4%) NYHA III-IV: 62 (64.6%) |
NYHA III-IV |
NYHA I-II |
All-cause mortality |
2.3 ± 1.7 years |
NYHA III-IV: HR = 2.39; CI: 0.95-6.01 |
Low |
| Rassi et al., 2006 |
Retrospective cohort |
Four-hundred twenty-four patients with chronic Chagas cardiomyopathy; aged 47 ± 11. NYHA I-IV: n = 380 (89.6%) NYHA III-IV: n = 44 (10.4%) |
NYHA III-IV |
NYHA I-II |
All-cause mortality |
7.9 ± 3.2 years |
NYHA III-IV: HR = 4.05; CI: 2.46-6.67; p ≤ 0.001 |
Moderate |
| Theodoropoulo et al., 2008 |
Prospective cohort |
One-hundred twenty-seven patients with chronic systolic heart failure secondary to Chagas cardiomyopathy; aged 54 ± 15; LVEF: 33% ± 11%. NYHA IV: 28 (22%) |
NYHA IV |
NYHA I-III |
All-cause mortality |
25 ± 19 months |
NYHA IV: HR = 1.92; CI: 1.02-3.56; p = 0.034 |
Low |